MedBiome News and Technology Updates / Founders of MedBiome receive 2.9M$ to further develop the RapidAIM microbiome drug screening platform

Founders of MedBiome receive 2.9M$ to further develop the RapidAIM microbiome drug screening platform

Published on: 26 February, 2019

Dr. Daniel Figeys, Dr. Alain Stintzi and their teams at the University of Ottawa are further developing the RapidAIM platform. The team is currently developing commercial applications, which include a fully automated, high-throughput prototype of the RapidAIM platform.

Innovations on human gut microbiome based drug discoveries

MedBiome focuses on the development of drugs that target the human microbiome. Our mission is to identify drugs that target the microbiome to improve human health.

MedBiome was launched in 2018 as the result of technologies developed at the University of Ottawa.

MedBiome is located in Ottawa, ON, Canada.

© 2019. MedBiome, Inc. All Rights Reserved.

Quick Links

Admin Access

  • Log In
MicroBiome Inc. LOGO